The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
== History == In 1799, British chemist Charles Hatchett experimented with decalcifying the shells of various crustaceans, finding that a soft, yellow and cartilage-like substance was left behind that is now known to be chitin. In 1859, French physiologist Charles Marie Benjamin Rouget found that boiling chitin in potassium hydroxide solution could deacetylate it to produce a substance that was soluble in dilute organic acids, that he called chitine modifiée. In 1894, German chemist Felix Hoppe-Seyler named the substance chitosan. From 1894 to 1930 there was a period of debate and confusion over the exact composition of chitin and particularly whether animal and fungal forms were the same chemicals. In 1930 the first chitosan films and fibres were patented but competition from petroleum-derived polymers limited their uptake. It was not until the 1970s that there was renewed interest in the compound, spurred partly by laws that prevented the dumping of untreated shellfish waste.
=== Artificial retina === The artificial retina of Professor José Sahel and his team at the Quinze-Vingts National Ophthalmology Hospital Centre aims to allow people with degenerative retinal disease, numbering 1.5 million in 2008, to accomplish everyday activities. Placed under the existing retina, it directly stimulates the neurons, replacing defective cells. These implants should eventually allow patients to recognize faces, read large print and move independently in a restricted environment. The challenge for the Altran teams was to find solutions to produce artificial retina in series, in order to bring solutions to the widest number of patients.
Aristotle in 350 BC in his History of animals noted the habits of bird migration, moulting, egg laying, and lifespans, as well as compiling a list of 170 different bird species. However, he also introduced and propagated several myths, such as the idea that swallows hibernated in winter, although he noted that cranes migrated from the steppes of Scythia to the marshes at the headwaters of the Nile. The idea of swallow hibernation became so well established that even as late as in 1878, Elliott Coues could list as many as 182 contemporary publications dealing with the hibernation of swallows and little published evidence to contradict the theory. Similar misconceptions existed regarding the breeding of barnacle geese. Their nests had not been seen, and they were believed to grow by transformations of goose barnacles, an idea that became prevalent from around the 11th century and noted by Bishop Giraldus Cambrensis (Gerald of Wales) in Topographia Hiberniae (1187). Around 77 AD, Pliny the Elder described birds, among other creatures, in his Historia Naturalis. The earliest record of falconry comes from the reign of Sargon II (722–705 BC) in Assyria. Falconry is thought to have made its entry to Europe only after 400 AD, brought in from the east after invasions by the Huns and Alans. Starting from the eighth century, numerous Arabic works on the subject and general ornithology were written, as well as translations of the works of ancient writers from Greek and Syriac.
Sources: en.wikipedia.org
=== Advantages of monochiral CNTs === Monochiral CNTs have the advantage that they contain fewer or no impurities, and well-defined non-congested optical spectra. This allows creation of CNT-based biosensors with higher sensitivity and selectivity. For example, monochiral SWCNTs are necessary for multiplexed and ratiometric sensing schemes with enhanced sensitivity and biocompatibility.
=== 22 July === Ukrainian drones set fire to an oil refinery at Tuapse, Krasnodar Krai. Russian officials claimed the fire was put out, with no casualties and no “serious damage”. Russian air defence shot down some 75 drones over night over the Black and Azov Seas and over Belgorod, Voronezh, Smolensk and Rostov Oblasts. Mamuka Mamulashvili, the commander of the pro-Ukrainian militia Georgian National Legion, claimed that the State Security Service of Georgia placed about 300 members of the group on a wanted list. Boeing and Antonov signed a memorandum of understanding to collaborate on drone production and maintenance.
=== Imaging Methods Core Facility === The Integrated Microscopy Core Facility (IMCF) provides fluorescence microscopy, electron microscopy, and flow cytometry services. The facility offers training, instrument access, and consulting services for experimental design, sample preparation, and data analysis. It also organizes courses on microscopic techniques.
Expectations diminished as a result of numerous failed replications, the retraction of several previously reported positive replications, and the identification of methodological flaws and experimental errors in the original study. By late 1989, most scientists considered cold fusion claims dead, and cold fusion subsequently gained a reputation as pathological science. In 1989 the United States Department of Energy (DOE) concluded that the reported results of excess heat did not present convincing evidence of a useful source of energy and decided against allocating funding specifically for cold fusion. A second DOE review in 2004, which looked at new research, reached similar conclusions and did not result in DOE funding of cold fusion. Presently, since articles about cold fusion are rarely published in peer-reviewed mainstream scientific journals, they do not attract the level of scrutiny expected for mainstream scientific publications. Some interest in cold fusion has continued through the decades—for example, a Google-funded failed replication attempt was published in a 2019 issue of Nature. A small community of researchers continues to investigate it, often under the alternative designations low-energy nuclear reactions (LENR) or condensed matter nuclear science (CMNS).
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.